Can I Take Quercetin with Brisdelle (Paroxetine 7.5 mg)?

What Is Brisdelle and Why Do Menopausal Women Take It?

Brisdelle is the only non-hormonal, FDA-approved prescription option specifically labeled for moderate-to-severe vasomotor symptoms (hot flashes and night sweats) in menopause. It contains paroxetine mesylate at 7.5 mg, a lower dose than the 20-40 mg used in depression treatment. The FDA approved it in June 2013 after the SYMPHONY trial showed it reduced mean hot-flash frequency by approximately 33-74% more than placebo over 12 weeks in postmenopausal women.

That lower 7.5 mg dose matters. It was chosen partly to minimize side effects that occur at antidepressant doses, including sexual dysfunction and withdrawal symptoms. But it still shares paroxetine's full pharmacological profile, meaning it still inhibits CYP2D6, it still has mild anticholinergic and antihistaminergic activity, and it still interacts with drugs or supplements that touch the same enzyme pathways.

Who Is Typically Taking Brisdelle?

Most Brisdelle users are women in perimenopause or postmenopause who either cannot or prefer not to use hormone therapy. Common reasons include a personal or family history of estrogen-receptor-positive breast cancer, contraindications to estrogen, or simply a preference for non-hormonal management. The Menopause Society (NAMS) 2023 position statement lists low-dose paroxetine as a recommended non-hormonal option for vasomotor symptoms, alongside other SSRIs and SNRIs, gabapentin, and the newer neurokinin-3 receptor antagonist fezolinetant.

Why Women in Midlife Often Add Supplements Like Quercetin

Women in the menopause transition frequently reach for supplements alongside prescriptions. A 2020 NAMS survey found that more than 70% of menopausal women use at least one dietary supplement, most without telling their prescriber. Quercetin is one of the more popular choices because it is marketed for antioxidant, anti-inflammatory, and antihistamine-like effects. Some women take it hoping it will reduce allergy symptoms that seem to worsen in perimenopause, a real phenomenon tied to declining estradiol's effect on mast cells.

What Is Quercetin and How Does It Work in the Body?

Quercetin is a polyphenol flavonoid found naturally in red onions, capers, apples, and green tea. As a supplement, it is sold in doses ranging from 250 mg to 1,000 mg per capsule. It is also sold in a more bioavailable form called quercetin phytosome or as quercetin dihydrate.

How the Body Processes Quercetin

Quercetin is absorbed in the small intestine and metabolized primarily by intestinal and hepatic CYP enzymes, including CYP3A4, CYP2C8, and to a lesser degree CYP1A2. Critically, quercetin does not just get metabolized by CYP3A4. It also inhibits CYP3A4 activity in a dose-dependent manner. A 2012 in vitro study published in Drug Metabolism and Disposition found quercetin to be a moderate inhibitor of CYP3A4 with an IC50 in the low micromolar range, a concentration achievable with standard oral supplementation at 500-1,000 mg doses.

The Antihistamine Angle

Quercetin also has documented H1-receptor stabilizing properties. It inhibits mast-cell degranulation and reduces histamine release, which is partly why it is marketed as a natural antihistamine. Paroxetine at 7.5 mg has its own mild H1-receptor antagonist activity. Whether additive pharmacodynamic effects at the H1 receptor translate to any clinically noticeable problem (extra sedation, dry eyes, constipation) is not established by human trial data, but the mechanism exists on paper.

The CYP3A4 Interaction: What Actually Happens

This is where the pharmacokinetics get specific. Paroxetine is primarily metabolized by CYP2D6, not CYP3A4. That distinction is important. If quercetin were only a CYP3A4 inhibitor, the direct metabolic interaction with paroxetine would be limited, because paroxetine's main clearance pathway runs through CYP2D6.

Why CYP3A4 Still Matters Here

CYP3A4 contributes a minor secondary clearance route for paroxetine, and CYP3A4 inhibition by quercetin could modestly slow that secondary route. The more clinically relevant CYP concern is the reverse: paroxetine is a potent CYP2D6 inhibitor itself. If you are taking any other drug that is a CYP2D6 substrate alongside both paroxetine and quercetin, the compounding inhibition could create unexpected drug accumulation in a third medication. Examples of CYP2D6-sensitive drugs many menopausal women use include tamoxifen, codeine, and some beta-blockers.

What Does Quercetin's CYP3A4 Inhibition Mean in Practice?

For your Brisdelle itself, the direct effect is likely small. For other medications in your stack, it depends entirely on what else you take. A 2020 systematic review in Biomedicine and Pharmacotherapy concluded that quercetin's in vivo CYP3A4 inhibitory effect in humans is weaker than in vitro data suggests, partly due to poor bioavailability and rapid phase-II conjugation in the gut wall. Still, individual variability is real, and women metabolize drugs differently across the menstrual cycle and with changing hormonal status at menopause.

Sex-Specific Pharmacokinetic Differences

CYP3A4 activity is approximately 20-30% higher in women than men due to estrogen's inductive effect on CYP3A4 expression. As estradiol declines in menopause, CYP3A4 activity in women may shift downward, potentially increasing susceptibility to CYP3A4 inhibitors like quercetin. This is an extrapolation from basic pharmacology because no clinical study has specifically measured quercetin-paroxetine interaction in postmenopausal women. That evidence gap is real, and you deserve to know it exists.

Pharmacodynamic Interaction: The Antihistamine and Sedation Question

Paroxetine 7.5 mg has mild H1 antagonism. Quercetin has mast-cell stabilizing and weak H1-modulating effects. Neither effect is strong on its own at these doses.

What You Might Notice

No published clinical trial has reported a significant sedation or anticholinergic burden from combining quercetin with low-dose paroxetine. Anecdotally, women taking both sometimes report mild next-day grogginess, dry mouth, or thickened nasal secretions, but these reports are not captured in any controlled dataset that WomanRx could identify. The pharmacodynamic concern is more theoretical than proven, and it is more likely to matter if you are also taking a first-generation antihistamine like diphenhydramine or a tricyclic antidepressant.

Serotonin Syndrome Risk

Quercetin does not meaningfully raise serotonin levels. It is not an MAOI, not a serotonin reuptake inhibitor, and does not inhibit serotonin metabolism at physiological supplement doses. The serotonin syndrome risk from quercetin plus Brisdelle is not a pharmacologically credible concern at the doses discussed here.

Who Should Be Most Cautious

Not every woman taking quercetin and Brisdelle faces the same level of risk. The following framework helps stratify who needs to be most careful.

Women Who Should Discuss This Combination with Their Prescriber Before Continuing

• You take tamoxifen. Paroxetine's CYP2D6 inhibition already reduces tamoxifen conversion to its active metabolite endoxifen by up to 64%. Adding a CYP3A4 inhibitor like quercetin to this combination creates additional metabolic complexity. If you are on Brisdelle for hot flashes during breast cancer treatment, this triple combination needs oncology and pharmacy review.
• You take a CYP2D6-sensitive cardiac drug like metoprolol or flecainide. Paroxetine plus quercetin may compound inhibition of clearance, raising drug plasma levels.
• You are a known CYP2D6 poor metabolizer. Paroxetine already accumulates more in this genotype. Adding secondary CYP3A4 inhibition from quercetin could push levels higher.
• You take quercetin at doses above 500 mg per day. The CYP3A4 inhibitory signal in human PK studies becomes more detectable at doses of 500 mg and above.

Women for Whom the Risk Is Likely Low

• You take quercetin at 250 mg or less per day with food, with no other CYP-sensitive medications in your regimen.
• You have been stable on Brisdelle for more than three months with no recent changes to your supplement stack.
• You have no concurrent use of tamoxifen, opioids, or narrow-therapeutic-index CYP2D6 substrates.

Even in this lower-risk group, disclosing quercetin use to your clinician is the right move. Supplement-drug interactions are consistently under-reported in standard medication reconciliation.

Dose Separation: Does Timing Your Doses Matter?

Dose separation is a common strategy for reducing pharmacokinetic supplement-drug interactions, particularly those mediated by intestinal enzyme inhibition. Quercetin's CYP3A4 inhibition occurs partly at the intestinal wall during absorption. Taking quercetin and Brisdelle at very different times of day may reduce peak overlap in the intestinal lumen.

Brisdelle is taken at bedtime. Quercetin is often taken with meals at breakfast or lunch. This natural timing difference already creates several hours of separation and may reduce but does not eliminate any intestinal CYP3A4 overlap. There is no published clinical trial testing a specific dose-separation window for quercetin and paroxetine. A separation of at least four to six hours is a reasonable general principle for reducing intestinal CYP interactions with flavonoids, extrapolated from studies on CYP3A4-sensitive drugs with grapefruit flavonoids.

Pregnancy, Lactation, and Contraception: Required Reading If You Are in Your Reproductive Years

Brisdelle is FDA Pregnancy Category D. This is not a precautionary soft warning. There is positive evidence of human fetal risk. Paroxetine use in the first trimester has been associated with a small but real increased risk of cardiac malformations, particularly ventricular septal defects, in observational studies including a large Swedish registry analysis. The FDA issued a public health advisory on paroxetine and congenital cardiac malformations based on these findings.

Paroxetine is the SSRI most consistently associated with teratogenicity risk among its class. If you are in perimenopause and still having cycles, even irregular ones, pregnancy remains possible. You need reliable contraception while taking Brisdelle. If you are trying to conceive, Brisdelle must be stopped, and a different non-hormonal strategy for hot flashes should be discussed with your clinician.

Neonatal Effects If Taken Later in Pregnancy

Paroxetine exposure in the third trimester is associated with neonatal adaptation syndrome: jitteriness, feeding difficulty, respiratory distress, and hypoglycemia in the newborn. These effects are typically transient but require monitoring. The prescribing information for Brisdelle states that neonates exposed to SSRIs late in pregnancy may require prolonged hospitalization, respiratory support, and tube feeding.

Breastfeeding and Paroxetine

Paroxetine does transfer into breast milk. Relative infant dose estimates range from 0.5% to 2.8% of the maternal dose, which is generally below the 10% threshold considered acceptable for most drugs in lactation. Paroxetine is considered one of the better-studied SSRIs in lactation and has not been associated with adverse infant outcomes in most published studies. Still, the labeled indication for Brisdelle is vasomotor symptoms of menopause. A lactating woman experiencing hot flashes postpartum is in a different clinical context. Brisdelle is not studied in postpartum women, and postpartum hot flashes are driven by different hormonal dynamics than menopausal ones.

Discuss with a lactation-informed clinician before using Brisdelle postpartum.

Quercetin in Pregnancy and Lactation

Quercetin at food-derived levels is not a pregnancy concern. High-dose quercetin supplements have not been studied adequately in pregnant or lactating women. Until data exist, high-dose quercetin supplements should be avoided in pregnancy. Quercetin does appear in breast milk in small amounts after dietary exposure, but supplement-dose transfer has not been characterized.

What to Tell Your Clinician and What to Expect from the Conversation

Many prescribers do not ask about supplements during a routine visit. You may need to raise it directly. Here is specific language you can use:

"I'm taking quercetin at [X mg] per day, usually with breakfast. I know it can affect CYP3A4. Can we check whether that creates any concern with my Brisdelle or any other medication in my chart?"

Your clinician or pharmacist can run a full drug-supplement interaction check using tools like Lexicomp or Natural Medicines database (formerly Natural Standard), both of which flag a moderate interaction between quercetin and CYP3A4-metabolized drugs.

If you are already taking both without any obvious side effects, that is reassuring, but it does not mean no interaction is occurring. Some pharmacokinetic interactions are asymptomatic until a third variable changes, such as a new prescription, a dose change, or a shift in your health status.

Monitoring: What to Watch For

If you continue taking quercetin and Brisdelle together, pay attention to:

• Increased side effects of paroxetine: nausea, excessive sedation, dry mouth, blurred vision, constipation, or palpitations may indicate higher-than-expected paroxetine exposure.
• Reduced hot-flash control: if Brisdelle seems to stop working, it could theoretically signal altered drug levels, although reduced efficacy is more commonly due to disease progression or missed doses.
• Any new medication additions: adding a CYP2D6 or CYP3A4-sensitive drug to an existing Brisdelle-quercetin combination is the scenario most likely to produce a clinically significant interaction.

There is no standard blood level monitoring for paroxetine 7.5 mg in menopause management. Therapeutic drug monitoring is not part of routine Brisdelle prescribing.

Alternatives If You Want to Avoid the Interaction Entirely

If you are concerned about the quercetin-Brisdelle interaction, you have two directions:

If Hot-Flash Control Is Your Priority

Ask your clinician whether quercetin is essential. If you are taking it primarily for allergy symptoms, a low-dose prescription antihistamine like cetirizine (Zyrtec) is better studied and has a more predictable interaction profile with paroxetine. If you are taking quercetin for general antioxidant purposes, dietary sources (red onions, capers, apples) provide quercetin without the higher CYP inhibitory doses seen with supplements.

If You Want to Keep Quercetin

Discuss whether Brisdelle is still the best non-hormonal option for your hot flashes. Fezolinetant (Veozah), approved by the FDA in May 2023 for moderate-to-severe vasomotor symptoms, works at the neurokinin B pathway and does not share CYP2D6/CYP3A4 metabolism with quercetin in the same way. The SKYLIGHT 1 and SKYLIGHT 2 trials demonstrated significant reductions in hot-flash frequency compared to placebo. It carries its own drug interaction profile and contraindications, so it is not automatically a safer combination, but for a woman whose supplement stack is non-negotiable, it may be worth the conversation.

Escitalopram and venlafaxine are other non-hormonal options with less CYP2D6 inhibition than paroxetine, which may reduce the overall interaction risk picture if you stay on an SSRI or SNRI.

The Evidence Gap: A Candid Note

No published clinical trial has specifically studied the combination of quercetin and paroxetine 7.5 mg in menopausal women. Everything in this article about the pharmacokinetic interaction is extrapolated from in vitro enzyme inhibition data, CYP3A4 interaction studies with quercetin in other drug contexts, and paroxetine's known pharmacology. The 2022 Drug Interactions with Natural Products review calls for more human PK studies with flavonoids at supplement doses.

Women have been historically underrepresented in pharmacokinetic interaction studies, and menopausal women even more so. When your clinician says "we don't really know," that is an accurate statement grounded in a real gap in the research, not a dismissal.